Serological markers of liver cancer

Best Practice and Research: Clinical Gastroenterology

Volumn 19, Issue 1 SPEC. ISS., 2005, Pages 91-99

  Yuen, Man Fung ^a   Lai, Ching Lung ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Alpha fetoprotein; Des gamma carboxyprothrombin; Glypican 3; Hepatocellular carcinoma; Serological marker

Indexed keywords

AGGLUTININ; ALPHA FETOPROTEIN; BIOLOGICAL MARKER; DECARBOXYPROTHROMBIN; DIPEPTIDYL PEPTIDASE IV; GLYPICAN; VASCULOTROPIN;

CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CORRELATION FUNCTION; DIAGNOSTIC ACCURACY; DISEASE ACTIVITY; EARLY DIAGNOSIS; HUMAN; LENTIL; LIVER CELL CARCINOMA; PATIENT MONITORING; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY;

EID: 14744286203     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2004.10.003     Document Type: Review

References (71)

1. World Health Organization Prevention of Liver Cancer WHO Technical Report Series 1993 WHO Geneva
2. M.C. Kew Hepatocellular carcinoma. A century of progress Clin Liver Dis 4 2000 257-268
3. G.I. Abelev Production of embryonal serum alpha-globulin by hepatomas: review of experimental and clinical data Cancer Res 28 1968 1344-1350
4. K. Okuda K. Kotaoda H. Obata et al. Clinical observation during a relatively early stage of hepatocellular carcinoma, with special reference to serum α-fetoprotein levels Gastroenterology 69 1975 226-234
5. D.S. Chen J.l. Sung J.C. Sheu et al. Serum α-fetoprotein in the early stage human hepatocellular carcinoma Gastroenterology 86 1984 1404-1409
6. D. Imberti F. Fornari G. Sbolli et al. Hepatocellular carcinoma in liver cirrhosis. A prospective study Scand J Gastroenterol 28 1993 540-544
7. L. Buscarini G. Sbolli L. Cavanna et al. Clinical and diagnostic features of 67 cases of hepatocellular carcinoma Oncology 44 1987 93-97
8. D. Imberti F. Fornari G. Sbolli et al. Hepatocellular carcinoma inliver cirrhosis. A prospective study Scand J Gastroenterol 28 1993 540-544
9. J. Raedle W.K. Roth G. Oremek et al. Alpha-fetoprotein and p53 autoantibodies in patients with chronic hepatitis C Dig Dis Sci 40 1995 2587-2594
10. S. Gupta S. Bent J. Kohlwes Test characteristics of alpha-fetoprotein for decting hepatocellular carcinoma in patients with hepatitis C. A systemic review and critical analysis Ann Intern Med 139 2003 46-50
11. F. Trevisani P.E. D'Intino A.M. Morselli-Labate et al. Serum α-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: Influence of HBsAg and anti-HCV status J Hepatol 34 2001 570-575
12. A.S. Lok C.L. Lai α-Fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: Role in the early detection of hepatocellular carcinoma Hepatology 9 1989 110-115
13. M.F. Yuen C.C. Cheng I.J. Lauder et al. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience Hepatology 31 2000 330-335
14. M.F. Yuen C.L. Lai Screening for hepatocellular carcinoma: Survival benefit and cost-effectiveness Ann Oncol 14 2003 1463-1467
15. M. Sherman α-Fetoprotein: An obituary J Hepatol 34 2001 603-605
16. R. Tremolda L. Benevegnu C. Drago et al. Early detection of hepatocellular carcinoma in patients with cirrhosis by α-fetoprotein, ultrasound and fine-needle biopsy Hepatogastroenterology 36 1989 519-521
17. M. Gotoh T. Nakatani T. Masuda et al. Prediction of invasive activities in hepatocellular carcinomas with special reference to α-fetoprotein and des-α-carboxyprothrombin Jpn J Clin Oncol 33 2003 522-526
18. Y. Kioke Y. Shiratori S. Sato et al. Des-γ-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma Cancer 91 2001 561-569
19. M. Sakon M. Monden M. Gotoh et al. Relationship between pathologic prognostic factors and abnormal levels of des-gamma-carboxy prothrombin and alpha-fetoprotein in hepatocellular carcinoma Am J Surg 163 1992 251-256
20. R. Susehiro K. Sugimachi T. Matsumata Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha-fetoprotein Cancer 73 1994 2464-2671
21. E. Seregni C. Botti E. Bombardieri Biochemical characteristics and clinical applications of alpha-fetoprotein isoforms Anticancer Res 15 1995 1491-1499
22. Y. Aoyagi Carbohydrate-based measurements on alpha-fetoprotein in the early diagnosis of hepatocellular carcinoma Glycoconj J 12 1995 194-199
23. K. Taketa C. Sekiya M. Namiki et al. Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions Gastroenterology 99 1990 508-518
24. Y. Endo Lectin-binding analysis of serum alpha-fetoprotein: Predictive importance of the change of AFP sugar chain in the development of hepatocellular carcinoma T. Tobe H. Kameda M. Okudaira M. Ohto Y. Endo M. Mito E. Okamoto K. Tanikawa M. Kojiro Primary Liver Cancer in Japan 1993 Springer New York 163-173
25. K. Taketa Y. Endo C. Sekiya et al. A collaborative study for the evaluation of lectin-reactive alpha-fetoprotein in early detection of hepatocellular carcinoma Cancer Res 53 1993 5419-5423
26. F. Yamashita M. Tanaka S. Satomura et al. Prognostic significance of Lens culinaris agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinoma Gastroenterology 111 1996 996-1001
27. Y. Aoyagi O. Isokawa T. Suda et al. The fucosylation index of alpha-fetoprotein as a possible prognostic indicator for patients with hepatocellular carcinoma Cancer 83 1998 2076-2082
28. T. Kumada S. Nakano I. Takeda et al. Clinical utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in small hepatocellular carcinoma: special reference to imaging diagnosis J Hepatol 30 1999 125-300
29. K. Hayashi T. Kumada S. Nakano et al. Usefulness of measurement of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein as a marker of prognosis and recurrence of small hepatocellular carcinoma Am J Gastroenterol 94 1999 3028-3033
30. P.J. Johnson N. Leung P. Cheng et al. 'Hepatoma-specific' alpha-fetoprotein may permit preclinical diagnosis of malignant change in patients with chronic liver disease Br J Cancer 75 1997 236-240
31. L.J. Burditt M.M. Johnson P.J. Johnson R. Williams Detection of hepatocellular carcinoma-specific alpha-fetoprotein by isoelectric focusing Cancer 74 1994 25-29
32. S. Ho P. Cheng J. Yuen et al. Isoelectric focusing of alphafetoprotein in patients with hepatocellular carcinoma-frequency of specific banding patterns at non-diagnostic serum levels Br J Cancer 73 1996 985-988
33. P.J. Johnson T.C. Poon N.M. Hjelm et al. Structures of disease-specific serum alpha-fetoprotein isoforms Br J Cancer 83 2000 1330-1337
34. T.C. Poon T.S. Mok A.T. Chan et al. Quantification and utility of monsialylated alpha-fetoprotein in the diagnosis of hepatocellular carcinoma with nondiagnostic serum total alpha-fetoprotien Clin Chem 48 2002 1021-1027
35. M. Ono H. Ohat M. Ohhira et al. Measurement of immunoreactive prothrombin precursor and vitamin-K dependent gamma-carboxylation in human hepatocellular tissues: Decreased carboxylation of prothrombin precursor as a cause of des-gamma-carboxyprothrombin synthesis Tumour Biol 11 1990 319-326
36. H.A. Liebman Isolation and characterization of a hepatoma-associated abnormal (des-gamma-carboxy) prothrombin Cancer Res 49 1989 6493-6497
37. H.A. Liebman B.C. Furie M.J. Tong et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma N Engl J Med 310 1984 1427-1431
38. F. Nomura M. Ishijima A. Horikoshi et al. Determination of serum des-gamma-carboxyprothrombin levels in patients with small-sized hepatocellular carcinoma. Comparison of the conventional enzyme immunoassay and two modified methods Am J Gastroenterol 91 1996 1380-1383
39. I.C. Weitz H.A. Liebman Dex-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma Hepatology 18 1993 990-997
40. H. Suzuki Y. Akahane M. Tanaka et al. Clinical evaluation of PIVKA-II kit (ED-036) Kan Tan Sui 33 1996 1069-1076
41. K. Takatsu T. Nakanishi K. Watanebe et al. Development and performance of an assay kit for PIVKA-II (ED-038) by ECL technique Jpn J Clin Exp Med 73 1996 2656-2664
42. K. Soga T. Watanebe K. Aikawa et al. Serum des-gamma-carboxyprothrombin level by a modified enzyme immunoassay method in hepatocellular carcinoma: Clinical significance in small hepatocellular carcinoma Hepatogastroenterology 45 1998 1737-1741
43. F. Nomura M. Ishijima K. Kuwa et al. Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma Am J Gastroenterol 94 1999 650-654
44. R. Nomura M. Ishijima A. Horikoshi et al. Determination of serum des-gamma-carboxy prothrombin levels in patients with small-sized hepatocellular carcinoma: Comparison of the conventional enzyme immunoassay and two modified methods Am J Gastroenterol 91 1996 1380-1383
45. S.L. Tsai G.T. Huang P.M. Yang et al. Plasma des-gamma-carboxyprothrombin in the early stage of hepatocellular carcinoma Hepatology 11 1990 481-488
46. G.L. Grazi A. Mazziotti C. Legnani et al.The role of tumor markers in the diagnosis of hepatocellular carcinoma with special reference to the des-gamma-carboxyprothrombin Liver Transpl Surg 1 1995 249-255
47. Y. Takikawa K. Suzuki K. Yamazaki et al. Plasma abnormal prothrombin (PIVKA-II): A new and reliable marker for the detection of hepatocellular carcinoma J Gastroenterol Hepatol 7 1992 1-6
48. S. Fujiyama K. Izuno K. Yamasaki et al. Determination of optimum cutoff levels of plasma des-gamma carboxy prothrombin and serum alpha-fetoprotein for the diagnosis of hepatocellular carcinoma using receiver operating characteristics curves Tumour Biol 13 1992 316-323
49. M. Ishii H. Gama N. Chida et al. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group Am J Gastroenterol 95 2000 1036-1040
50. A. Kasahara N. Hayashi H. Fusamoto et al. Clinical evaluation of plasma des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumours of various sizes Dig Dis Sci 38 1993 2170-2176
51. Y. Mita Y. Aoyagi M. Yanagi et al. The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma Cancer 82 1998 1643-1648
52. T. Nakagawa T. Seki T. Shiro et al. Clinicopathologic significance of protein induced vitamin K absence or antagonist II ans alpha-fetoprotein in hepatocellular carcinoma Int J Oncol 14 1999 281-286
53. T. Suehiro K. Sugimachi T. Matsumata et al. Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma Cancer 73 1994 2464-2471
54. S. Fujiyama M. Tanaka S. Maeda et al. Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma Oncology 62 2002 57-63
55. J.A. Marrero G.L. Su W. Wei et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients Hepatology 37 2003 1114-1121
56. Y. Shimauchi M. Tanaka R. Kuromatsu et al. A simultaneous monitoring of Lens culinaris agglutinin A-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin as an early diagnosis of hepatocellular carcinoma in the follow-up of cirrhotic patients Oncol Rep 7 2000 249-256
57. J. Filmus J. Church R.N. Buick Isolation of a cDNA corresponding to a developmentally regulated transcript in rat intestine Mol Cell Biol 8 1988 4243-4249
58. J. Filmus S.B. Selleck Glypicans: Proteoglycans with a surprise J Clin Invest 108 2001 497-501
59. M. Bernfield M. Gotte P.W. Park et al. Functions of cell surface heparan sulfate proteglycans Annu Rev Biochem 68 1999 729-777
60. G. Pilia R.M. Hughes-Benzie P. Mackenzie et al. Mutations in GPC3, a glypican gene cause the Simpson-Golabi-Behmel overgrowth syndrome Nat Genet 12 1996 241-247
61. A.D. Gonzalez M. Kaya W. Shi et al. OCI-5/GPC3, a glypican encoded by a gene that is mutated in the Simpson-Golabi-Behmel overgrowth syndrome, induces apoptosis in a cell line-specific manner J Cell Biol 141 1998 1407-1414
62. H.C. Hsu W. Cheng P.L. Lai Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: Biological significance and temporospatial distribution Cancer Res 57 1997 5179-5184
63. Z.W. Zhu H. Friess L. Wang et al. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders Gut 48 2001 558-564
64. T. Nakatsura Y. Yoshitake S. Senju et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker Biochem Biophys Res Commun 306 2003 16-25
65. Y.K. Sung S.Y. Hwang M.K. Park et al. Glypican-3 is overexpressed in human hepatocellular carcinoma Cancer Sci 94 2003 259-262
66. M. Capurro I.R. Wanless M. Sherman et al. Glypican-3: A novel serum and histochemical marker for hepatocellular carcinoma Gastroenterology 125 2003 89-97
67. S.D. Ryder P.M. Rizzi M. Volkmann et al. Use of specific ELISA for the detection of antibodies directed against p53 protein in patients with hepatocellular carcinoma J Clin Pathol 49 1996 295-299
68. A.M. Attallah M.M. Abdel-Aziz A.M. El-Sayed A.A. Tabll Detection of serum p53 protein in patients with different gastrointestinal cancers Cancer Detect Prev 27 2003 127-131
69. J. Kojima Y. Ueno H. Kasugai et al. Glycylproline dipeptidyl aminopeptidase and gamma-glutamyl transpeptidase in human hepatic cancer and embryonal tissues Clin Chim Acta 167 1987 285-291
70. R.Z. Ni J.F. Huang M.B. Xiao et al. Glycylproline dipeptidyl aminopeptidase isoenzyme in diagnosis of primary hepatocellular carcinoma World J Gastroenterol 9 2003 710-713
71. X.M. Li Z.Y. Tang L.X. Qin et al. Serum vascular endothelial growth factor is a predictor of invasion and metastasis in hepatocellular carcinoma J Exp Clin Cancer Res 18 1999 511-517